Brooks Laboratories stake sale nets ₹106 crore in 2026

The latest development

Brooks Laboratories Limited (NSEI: BROOKS) has disclosed a partial monetisation of its holding in associate company Brooks Steriscience Limited (BSL). The company said its board approved the sale of 51,220 equity shares of BSL to Steriscience Specialties Private Limited.

The transaction, disclosed under Regulation 30 (LODR) through exchange filings, is positioned as a funding move, with Brooks stating that the cash proceeds will be used for expansion and general corporate purposes. The sale follows earlier corporate restructuring activity involving BSL that did not progress in its then-current form.

Deal snapshot: buyer, seller, and consideration

Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories for a total value of ₹110 crore. Brooks also disclosed that a cash consideration of ₹106 crore will be paid by Steriscience Specialties.

On a per-share basis, Brooks stated it approved the sale of 51,220 shares at ₹20,760 per share, which it said would fetch approximately ₹106 crore. The disclosures indicate the transaction is a cash deal, with consideration and pricing clearly specified.

What changes in ownership after closing

Upon completion of the transaction, Steriscience Specialties Private Limited is expected to hold 67.33% in Brooks Steriscience Limited. Brooks Laboratories’ stake in BSL reduces from 49% to 32.67% after the partial sale.

This change is notable because it reshapes BSL’s shareholder structure, moving Steriscience Specialties further into a majority position. For Brooks Laboratories, the reduced stake changes the level of exposure to BSL while providing a sizeable cash inflow.

Approvals and conditions attached to the sale

Brooks indicated the transaction remains subject to customary documentation and regulatory clearances. It also noted that the transaction is subject to approval of the merger agreement by the target board and approval by the regulatory board or committee.

These conditions matter for timelines because they imply the sale is not yet fully consummated at the time of disclosure, even though a board approval and pricing have been communicated.

Memorandum of understanding and the sequence of disclosures

Brooks Laboratories disclosed multiple related events in 2026. The stake sale approval and the buyer’s agreement to acquire the additional 16.33% stake were dated June 19, 2026.

Separately, Brooks Laboratories said it signed a binding memorandum of understanding with Steriscience Specialties Private Limited and Brooks Steriscience Limited on July 16, 2026. The disclosures, read together, show a structured process moving from board approval and sale terms to formal documentation.

How this links to the earlier composite merger scheme

The partial monetisation comes after a composite scheme of arrangement and amalgamation involving BSL was abandoned in May 2026. Brooks Laboratories informed exchanges that BSL decided not to pursue the proposed composite scheme of arrangement and amalgamation in its current form.

Brooks stated that BSL’s board took this decision at its meeting held on May 14, 2026, describing it as being in the best interest of stakeholders. The earlier scheme had contemplated a multi-entity restructuring with OneSource Specialty Pharma Limited described as a key transferee.

What was in the proposed scheme, and what approvals it had

Brooks’ disclosures noted that the proposed composite scheme had received in-principle approval from the National Stock Exchange of India Limited and BSE Limited on February 6, 2026. It also stated that the no-objection letters from NSE and BSE were valid for six months.

The scheme was described as a merger by absorption, involving Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited, and Onesource Specialty Pharma Limited.

Key details at a glance

Timeline of major events mentioned in filings

Market impact and why investors track this

The most direct financial datapoint from the disclosures is the expected cash inflow of about ₹106 crore to Brooks Laboratories. The company has stated the proceeds are intended for expansion and general corporate purposes, which makes the deployment of funds a key follow-up item for shareholders.

From a structure standpoint, the deal reduces Brooks’ ownership in BSL to 32.67%, while Steriscience Specialties moves to 67.33% ownership. That shift can be material for investors tracking how value and control over BSL are distributed after the earlier composite merger scheme was not pursued in its existing form.

What to watch next

The sale is subject to documentation and regulatory clearances, and Brooks has also referenced target board and regulatory board or committee approvals. Investors typically watch for final completion updates through further exchange filings.

Separately, the history of the composite scheme and its withdrawal by BSL suggests that corporate structuring has been an active area around the Steriscience group. Any future steps, if announced, are likely to come through formal filings, board decisions, and exchange disclosures.

Conclusion

Brooks Laboratories’ approved sale of 51,220 shares in Brooks Steriscience to Steriscience Specialties is a clear, cash-generating transaction, expected to bring in about ₹106 crore and reduce Brooks’ stake to 32.67%. The next milestones are completion-related approvals and any subsequent disclosures on closing and the use of proceeds for expansion and corporate needs.